Skip to main content

HomeResearchCompareAngiotensin (1-7) vs NAD+

Peptide Comparison

Angiotensin (1-7) vs NAD+

Both are Longevity & Cellular peptides.

Angiotensin (1-7)

Ang-(1-7)

LongevityInvestigationalResearch Only

Half-life: ~9–10 sec (rat)

No providers listed yet

Full Angiotensin (1-7) profile →
vs

NAD+

NAD

LongevityMixed

Half-life: ~1–2 hours (IV); variable (oral)

447 providers listed

Full NAD+ profile →
Bottom line

NAD+ carries stronger published evidence (RCT, 8 key studies) than Angiotensin (1-7) (RCT, 15); both are research compounds.

Quick Verdict

Angiotensin (1-7)

Evidence

Clinical

Half-life

~9–10 sec (rat)

NAD+

Evidence

Established Clinical

Half-life

~1–2 hours (IV); variable (oral)

Which One Should You Choose?
Your goalBetter option
Stronger clinical evidenceNAD+
Further along in FDA reviewAngiotensin (1-7)
Less frequent dosing (longer half-life)Angiotensin (1-7)
Oral administration optionNAD+
More provider options (0 vs 447)NAD+

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison
Angiotensin (1-7)
NAD+
Mechanism Family
Longevity & Cellular
Longevity & Cellular
Half-life
~9–10 sec (rat)
~1–2 hours (IV); variable (oral)
FDA Status
investigational
evaluated not recommended
Admin Routes
subcutaneous, intravenous
intravenous, subcutaneous, oral
Availability
Research Only
Mixed
Providers
None listed
447 listed
FDA Update
Sep 2019
Avail. Notes
Available OTC as supplement. IV/injection forms offered by clinics without FDA evaluation as a drug.
Research Evidence

Angiotensin (1-7)

ClinicalRCT · 15 key studies · most recent 2026

NAD+

Established ClinicalRCT · 8 key studies · most recent 2026
Research Citations

About Angiotensin (1-7)

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Research Areas
cardiovascular protectionanti-fibroticvasodilationinsulin sensitivitykidney protection

About NAD+

NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.

Research Areas
NAD+/NADH ratio restoration supporting cellular energy productionsirtuin pathway activation (SIRT1–SIRT7) linked to aging researchDNA repair cofactor — PARP enzyme activity dependent on NAD+IV therapy context: $200–$1,000/session; oral NMN/NR as alternative routes
Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Angiotensin (1-7)

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

NAD+

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Angiotensin (1-7)

Not enough vendor pricing yet.

NAD+

$0.14/mg

$0.11$0.20 range

28 vendors

Find Providers

Where to source these peptides

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Angiotensin (1-7) vs NAD+ — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/angiotensin-1-7/nad-plus

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.